Jump to Main Content
Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma
- Feng, Mingqian, Gao, Wei, Wang, Ruoqi, Chen, Weizao, Man, Yan-Gao, Figg, William Douglas, Wang, Xin Wei, Dimitrov, Dimiter S., Ho, Mitchell
- Proceedings of the National Academy of Sciences of the United States of America 2013 v.110 no.12 pp. E1083
- antibodies, epitopes, hepatoma, humans, interphase, mice, therapeutics
- Glypican-3 (GPC3) has emerged as a candidate therapeutic target in hepatocellular carcinoma (HCC), but the oncogenic role of GPC3 in HCC is poorly understood. Here, we report a human heavy-chain variable domain antibody, HN3, with high affinity (K d = 0.6 nM) for cell-surface–associated GPC3 molecules. The human antibody recognized a conformational epitope that requires both the amino and carboxy terminal domains of GPC3. HN3 inhibited proliferation of GPC3-positive cells and exhibited significant inhibition of HCC xenograft tumor growth in nude mice. The underlying mechanism of HN3 action may involve cell-cycle arrest at G1 phase through Yes-associated protein signaling. This study suggests a previously unrecognized mechanism for GPC3-targeted cancer therapy.